Awakn Life Sciences Announces Voluntary Lock-up Agreement Extension with Management, Board of Directors and Key Shareholders

Toronto, Ontario–(Newsfile Corp. – January 4, 2022) – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat addiction, announced that management, the Board of Directors (“the Board”) and key shareholders (the “Lock-up Shareholders”) have voluntarily entered into a Lock…

Source